The Firm has pioneered patent litigation in India’s post TRIPS (the Agreement on Trade Related Aspects of Intellectual Property Rights) regime, advising, and acting on behalf of, leading international pharmaceutical companies on seminal matters including Section 3(d) of the Patents Act and the issue of compulsory licensing. More recently, telecom disputes involving Fair, Reasonable and Non-Discriminatory (FRAND) licensing agreements in Standard Essential Patents (SEPs) have been an area of focus. With one of the largest, most experienced patent litigation teams in the country, our capabilities include:
“On the contentious front, Remfry & Sagar has a real facility for hammering out favourable out-of-court settlements, but fights doggedly in court when necessary.”
IAM Patent 1000 2017
“Many can offer lower prices, but when stakes are high for multibillion-dollar companies, they will only give their patent issues to a time-honoured firm like Remfry & Sagar.”
IAM Patent 1000 2016
“Top-league specialists who offer expertise across a wide range of areas.”
Chambers Asia Pacific Guide 2017
As per the rules of the Bar Council of India, we are not permitted to solicit work or advertise in any manner. By proceeding further and clicking on “I Agree” below, the user acknowledges that the transmission, receipt or use of the information on our website does not tantamount to solicitation, advertisement, inducement or personal communication of any sort for and on behalf of the Firm so as to create an attorney-client relationship.
The information provided herein should not be interpreted as legal advice, for which the user must make independent inquiries. Whilst every effort has been taken to ensure the accuracy of the contents of this website, Remfry & Sagar disclaims all liability arising from reliance placed by the user or any other third party on the information contained therein.